Rancher Labs announced that it recorded 161 percent year-on-year revenue growth and increased its number of customers by 52 percent since the start of 2019, the best first half of a year since the company launched its first product in 2016. This rapid growth demonstrates increasing industry-wide demand for Rancher Labs’ software, which allows users[…]
Sumitomo Chemical and Zymergen announced today they have signed a multi-year partnership to bring new specialty materials to the market. This collaboration between the two companies will enable the development of new materials to meet consumer trends in high-tech industries. Today, electronics makers and consumers seek devices that are lighter, smaller, more battery efficient, have[…]
February 8, 2019 TPTF invest in Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, in Series B-1 funding. Currently, Finch is actively enrolling patients with recurrent Clostridium difficile (C. difficile) infection Phase II clinical study to assess the safety and efficacy of an investigational drug CP101. The study drug is an oral capsule that is administered in a single dose.
Apexigen today announced a collaboration with Columbia University Irving Medical Center on a new Phase 2 study for its lead immuno-oncology (I-O) therapeutic APX005M, a monoclonal antibody targeting CD40, in combination with doxorubicin and olaratumab in patients with advanced sarcomas. The trial is being funded by Apexigen and is being conducted by researchers at Columbia[…]
TPTF invested in Zymergen, the world’s first molecular manufacturing technology company, in Series C funding of over $400 million led by returning investor SoftBank Vision Fund. The round also welcomes new investors Goldman Sachs and Hanwha Asset Management, as well as returning investors, DCVC (Data Collective), True Ventures, Two Sigma Ventures, DFJ and Innovation Endeavors.[…]
Quanergy Systems, Inc., a global leader in the development and manufacture of LiDAR sensors and smart sensing solutions, today announced it has secured Series C funding at a valuation exceeding $2 billion, with a global top-tier fund as the lead investor. Raising the Series C financing takes the company well beyond its planning horizons to[…]
Apexigen today announced the successful completion of its Series B and Series C financings in which it raised a total of $73 million. The $15 million Series B financing was led by Decheng Capital and the recent $58 million Series C financing was led by 3E Bioventures Capital, Virtus Inspire Ventures, and SV Tech Ventures.[…]
The MPB-1523 MRI contrast agent developed by “MegaPro Biomedical”, a start-up from ITRI, showed rapid progress. Despite having established for only 3 years, MegaPro Biomedical obtained the approval from the US Food and Drug Administration (FDA) to conduct Phase II of the clinical trial for its contrast agent. The contrast agent has passed the Investigational[…]
Apexigen today announced the initiation of patient enrollment in Phase 2 clinical trial in collaboration with the University of California San Francisco (UCSF). This trial is designed to evaluate Apexigen’s CD40 agonistic antibody, APX005M, in combination with multimodal treatment (chemotherapy and radiation therapy) in patients with resectable esophageal and gastroesophageal junction cancers.
Apexigen, Inc., — a clinical-stage biopharmaceutical company focusing on discovering and developing antibody-based therapeutics for the treatment of cancer with an emphasis on new Immuno-Oncology (I-O) agents, today announced the receipt of a milestone payment under a license agreement for its proprietary APXiMAB™ technology. The milestone payment was associated with the achievement of a clinical development[…]